# Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Canonical URL: https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-second-quarter-2026-financial-results-on-july-29-2026-56aa71ab
Ticker: AXGN
Company: AxoGen
Source: AxoGen
Published: 2026-07-15 11:00 EST
Original Source URL: https://ir.axogeninc.com/news-events/press-releases/detail/1023/axogen-inc-to-report-second-quarter-2026-financial-results-on-july-29-2026
## Summary

ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing…...

## Article Body
July 15, 2026 7:00am EDT

ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company's website at www.axogeninc.com .

About Axogen Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

Contact: Axogen, Inc. InvestorRelations@axogeninc.com

Source: Axogen, Inc. Released July 15, 2026
## Recent Company News
- 2026-07-15 11:00 EST — [Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026](https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-second-quarter-2026-financial-results-on-july-29-2026-56aa71ab) — Source: AxoGen
- 2026-06-25 13:46 EST — [Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference](https://biopharmsignal.com/news/AXGN/axogen-inc-to-participate-in-the-j-p-morgan-2026-healthcare-conference) — Source: AxoGen
- 2026-06-25 13:46 EST — [Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025](https://biopharmsignal.com/news/AXGN/axogen-inc-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2025) — Source: AxoGen
- 2026-06-25 13:46 EST — [Axogen Announces Proposed Public Offering of Common Stock](https://biopharmsignal.com/news/AXGN/axogen-announces-proposed-public-offering-of-common-stock) — Source: AxoGen
- 2026-06-25 13:46 EST — [Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock](https://biopharmsignal.com/news/AXGN/axogen-announces-pricing-of-upsized-124-million-public-offering-of-common-stock) — Source: AxoGen
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)